Skip to content
Biodatica
Start free

AbbVie

Gilbert, Arizona

OncologyPhase IIIListed · ABBV

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

3w agoTrial registeredJun 24, 2026Source filing (opens the source filing in a new tab)

Momentum

98no change

Momentum 98 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    May 26, 2026

    Healthy Volunteer · RECRUITING · sponsor: AbbVie · A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

    ClinicalTrials.gov · NCT07604558 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Apr 14, 2026

    Small Cell Lung Cancer · NOT_YET_RECRUITING · sponsor: AbbVie · A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    ClinicalTrials.gov · NCT07365241 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Apr 14, 2025

    Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer · RECRUITING · sponsor: AbbVie · A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    ClinicalTrials.gov · NCT06858813 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Dec 5, 2022

    Advanced Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT05599984 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Nov 1, 2021

    Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer · RECRUITING · sponsor: AbbVie · Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    ClinicalTrials.gov · NCT05005403 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Feb 13, 2020

    Cancer, Non-small Cell Lung Cancer (NSCLC) · TERMINATED · sponsor: AbbVie · An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT04189614 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources